TIGER'S TAKE: On our trading list. A good longer term biotech/drug stock. Due to its volatility, options trading around a position could be profitable. $IOVAIovance Biotherapeutics initiated with a Buy at StifelStifel analyst Benjamin Burnett started Iovance Biotherapeutics with a Buy rating and $27 price target. The analyst says his physician checks corroborate the view that the company's lifileucel and LN-145 data are "very good" and supportive of being the best therapeutic option in their respective advanced settings. He believes the market opportunity for an autologous tumor-infiltrating lymphocyte product in the advanced melanoma/cervical cancer setting can reach $2B-plus sales at peak.Source: (thefly.com) $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page.